AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32473339 — intervention group
Group type: COMPARATOR
Intervention: Standard magnification
Number of subjects: 151
Study 32473635 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoCIII concentration measured in chylomicron-free serum (postprandial)
Number of subjects: 195
Study 32473635 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoCIII concentration measured in chylomicron-free serum (fasting)
Number of subjects: 195
Study 32473635 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoCIII concentration measured in native serum (postprandial)
Number of subjects: 195
Study 32473635 — intervention group
Group type: EXPERIMENTAL
Intervention: ApoCIII concentration measured in native serum (fasting)
Number of subjects: 195
Study 32473681 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin plus hydroxychloroquine
Number of subjects: 928
Study 32473681 — intervention group
Group type: COMPARATOR
Intervention: Residence in Canada
Number of subjects: 928
Study 32473681 — intervention group
Group type: COMPARATOR
Intervention: Residence in the US-Midwest
Number of subjects: 928
Study 32473681 — intervention group
Group type: EXPERIMENTAL
Intervention: Age (per 10 years increase)
Number of subjects: 928
Study 32473681 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 928
Study 32473681 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smoker vs never smoked
Number of subjects: 928
Study 32473681 — intervention group
Group type: EXPERIMENTAL
Intervention: Two comorbidities vs none
Number of subjects: 928
Study 32473681 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG performance status of 2 or higher vs 0 or 1
Number of subjects: 928
Study 32473681 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cancer (progressing vs remission)
Number of subjects: 928
Study 32473888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary imaging-guided pre-dilation, stent sizing, and post-dilation (iPSP)
Number of subjects: 9525
Study 32473888 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 9525
Study 32474892 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV (live-attenuated Japanese encephalitis chimeric virus vaccine)
Number of subjects: 810
Study 32474892 — intervention group
Group type: EXPERIMENTAL
Intervention: JE-CV
Number of subjects: 810
Study 32474893 — intervention group
Group type: EXPERIMENTAL
Intervention: LightPower Taqman real-time PCR method
Number of subjects: 106
Study 32474893 — intervention group
Group type: EXPERIMENTAL
Intervention: Versant 2.0 line probe assay
Number of subjects: 106
Study 32474893 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined results of Versant and sequencing
Number of subjects: 106
Study 32474893 — intervention group
Group type: EXPERIMENTAL
Intervention: Versant 2.0 (using 5'UTR and core information)
Number of subjects: 106
Study 32475029 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 97
Study 32476053 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm infants (PTI)
Number of subjects: 29
Study 32476449 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I collagen matrix plus polyhexamethylene biguanide antimicrobial
Number of subjects: 0
Study 32476520 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone therapy with doses adjusted based on creatinine clearance (10 mg for moderate RI, CrCl 30-60 mL/min)
Number of subjects: 0
Study 32476520 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and dexamethasone therapy
Number of subjects: 0
Study 32476658 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based recovery-oriented mental health care (CMHC)
Number of subjects: 900
Study 32476658 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (CAU)
Number of subjects: 900
Study 32476659 — intervention group
Group type: EXPERIMENTAL
Intervention: pre-NDPP (enhanced enrollment)
Number of subjects: 1140
Study 32476659 — intervention group
Group type: COMPARATOR
Intervention: NDPP (usual care)
Number of subjects: 1140
Study 32477003 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma shared decision making (SDM) toolkit intervention
Number of subjects: 10
Study 32477003 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation by research nurses
Number of subjects: 10
Study 32477016 — intervention group
Group type: EXPERIMENTAL
Intervention: RADREMI dosing (SRS doses of 18 Gy for 0-2 cm lesions, 14 Gy for 2.1-3 cm lesions, and 12 Gy for 3.1-4 cm lesions)
Number of subjects: 0
Study 32477016 — intervention group
Group type: EXPERIMENTAL
Intervention: RADREMI dosing
Number of subjects: 0
Study 32477853 — intervention group
Group type: COMPARATOR
Intervention: Text messaging outreach alone
Number of subjects: 281
Study 32477853 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging with lottery for a 1-in-5 chance of winning $100 after FIT completion
Number of subjects: 281
Study 32478195 — intervention group
Group type: EXPERIMENTAL
Intervention: Exubera (EXU; insulin human [rDNA origin] Inhalation Powder)
Number of subjects: 1961
Study 32478195 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 1961
Study 32478205 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 781
Study 32478205 — intervention group
Group type: COMPARATOR
Intervention: Ticagrelor
Number of subjects: 781
Study 32478814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 1 mg/kg
Number of subjects: 28
Study 32478814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab 0.5 mg/kg
Number of subjects: 28
Study 32478814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (overall response rate)
Number of subjects: 28
Study 32478814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1-year progression-free survival)
Number of subjects: 28
Study 32478814 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (1-year overall survival)
Number of subjects: 28
Study 32479189 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with weekly cisplatin-based chemoradiotherapy
Number of subjects: 59
Study 32479307 — intervention group
Group type: EXPERIMENTAL
Intervention: Barriers to mental health service utilization (MHSU)
Number of subjects: 3358
Study 32479604 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 32479608 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 200-mg dose
Number of subjects: 8
Study 32479608 — intervention group
Group type: EXPERIMENTAL
Intervention: Artefenomel 300-mg dose (predicted)
Number of subjects: 8
Study 32479741 — intervention group
Group type: EXPERIMENTAL
Intervention: Constitutional thinness (CT) group
Number of subjects: 30
Study 32479741 — intervention group
Group type: COMPARATOR
Intervention: Normal-weight control group
Number of subjects: 30
Study 32480059 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C < 100 mg/dL (70-99 mg/dL)
Number of subjects: 13623
Study 32480059 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C < 70 mg/dL
Number of subjects: 13623
Study 32480059 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA1c < 7%
Number of subjects: 13623
Study 32480059 — intervention group
Group type: COMPARATOR
Intervention: Blood Pressure targets
Number of subjects: 13623
Study 32480405 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole gene deletions of MKRN3 identified in 2 subjects (13%): Patient A with complete deletion (pubertal onset at 7 years) and Patient B with a larger deletion involving MAGEL2, MKRN3, and NDN (pubertal onset at 5.5 years). Both deletions were paternally inherited.
Number of subjects: 16
Study 32481274 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrative Korean medicine treatment
Number of subjects: 1000
Study 32481400 — intervention group
Group type: COMPARATOR
Intervention: TL1A levels in the STEMI group
Number of subjects: 141
Study 32481400 — intervention group
Group type: COMPARATOR
Intervention: TL1A levels in the NSTEMI group
Number of subjects: 141
Study 32481400 — intervention group
Group type: COMPARATOR
Intervention: hs-CRP and MPO levels in UA, NSTEMI, and STEMI groups
Number of subjects: 141
Study 32481400 — intervention group
Group type: COMPARATOR
Intervention: Plasma IL-10 levels in UA, NSTEMI, and STEMI groups
Number of subjects: 141
Study 32481400 — intervention group
Group type: EXPERIMENTAL
Intervention: TL1A levels in coronary blood vs peripheral blood in STEMI and NSTEMI groups
Number of subjects: 141
Study 32481400 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of TL1A levels in coronary and peripheral blood
Number of subjects: 141
Study 32481400 — intervention group
Group type: EXPERIMENTAL
Intervention: TL1A levels correlation with cTnI, coronary thrombus burden, MACE
Number of subjects: 141
Study 32481400 — intervention group
Group type: EXPERIMENTAL
Intervention: TL1A levels correlation with IL-10 and Syntax score
Number of subjects: 141
Study 32482174 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary reverse mapping (ARM) technique
Number of subjects: 78
Study 32482382 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Insecurity (WI)
Number of subjects: 183
Study 32482382 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of Food Insecurity (FI), Water Insecurity (WI), and HIV
Number of subjects: 183
Study 32482616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after one-month dual antiplatelet therapy (DAPT)
Number of subjects: 7185
Study 32482616 — intervention group
Group type: COMPARATOR
Intervention: Conventional dual antiplatelet therapy (DAPT)
Number of subjects: 7185
Study 32482616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy after one-month DAPT
Number of subjects: 7185
Study 32482834 — intervention group
Group type: EXPERIMENTAL
Intervention: Pipeline Embolization Device with Shield technology (PED-Shield)
Number of subjects: 204
Study 32483359 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 0
Study 32483557 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebselen
Number of subjects: 0
Study 32483557 — intervention group
Group type: COMPARATOR
Intervention: Control (no Ebselen)
Number of subjects: 0
Study 32483558 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib
Number of subjects: 0
Study 32483680 — intervention group
Group type: EXPERIMENTAL
Intervention: Premixed fast-set tricalcium silicate putty (TotalFil FS putty) as root-end filling material
Number of subjects: 35
Study 32483680 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 35
Study 32483745 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper abdominal MR examinations using fat liver acquisition with volume acceleration-flexible (LAVA-Flex) sequence
Number of subjects: 570
Study 32483745 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper abdominal MR examinations using proton density fat fraction (PDFF) maps
Number of subjects: 570
Study 32483745 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper abdominal MR examinations
Number of subjects: 570
Study 32484413 — intervention group
Group type: EXPERIMENTAL
Intervention: Myocardial global longitudinal strain (GLS) at MRI
Number of subjects: 206
Study 32484413 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox regression analysis of MRI-derived myocardial strain
Number of subjects: 206
Study 32484435 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dithranol (anthralin)
Number of subjects: 0
Study 32484435 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32484517 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive CAD
Number of subjects: 1016
Study 32484517 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-obstructive CAD
Number of subjects: 1016
Study 32484517 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographically normal coronary arteries
Number of subjects: 1016
Study 32484517 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 1016
Study 32484517 — intervention group
Group type: COMPARATOR
Intervention: Obstructive CAD vs. ACS cohort
Number of subjects: 1016
Study 32484517 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of obstructive CAD
Number of subjects: 1016
Study 32484552 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant (10 mg for 1 week, titrated to 20 mg for 2 weeks)
Number of subjects: 19
Study 32484552 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 32484853 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-generated STOPP/START recommendations
Number of subjects: 204
Study 32485203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (esketamine) treatment for TRD
Number of subjects: 891
Study 32485203 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute psychoactive effects measured by CADSS
Number of subjects: 891
Study 32486385 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 860585 monotherapy (5-300 mg/day)
Number of subjects: 0
Study 32486385 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 860585 (40-220 mg/day) with 25 mg/day exemestane
Number of subjects: 0
Study 32486385 — intervention group
Group type: EXPERIMENTAL
Intervention: BI 860585 (80-220 mg/day) with 60-80 mg/m2 paclitaxel
Number of subjects: 0
Study 32487185 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 1078
Study 32487185 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index
Number of subjects: 1078
Study 32487185 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent viral load
Number of subjects: 1078
Study 32487185 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent CD4+/CD8+ ratio
Number of subjects: 1078
Study 32487185 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine exposure
Number of subjects: 1078
Study 32487185 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate exposure
Number of subjects: 1078
Study 32487218 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy and radiotherapy
Number of subjects: 65
Study 32487218 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Number of subjects: 65
Study 32487218 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC status at any timepoint
Number of subjects: 65
Study 32487218 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC patterns following treatment
Number of subjects: 65
Study 32487218 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of CTCs
Number of subjects: 65
Study 32487229 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumacaftor/Ivacaftor (LUM/IVA) for 1 month
Number of subjects: 0
Study 32487237 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine [TIMP-2]*[IGFBP7] measurements at 0h, 6h, 12h, and 24h
Number of subjects: 184
Study 32487237 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline urine [TIMP-2]*[IGFBP7] in persistent AKI group
Number of subjects: 184
Study 32487237 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical variables
Number of subjects: 184
Study 32487542 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil 35 mg/m²
Number of subjects: 793
Study 32487569 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus gemcitabine and cisplatin
Number of subjects: 32
Study 32487574 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (first-line or third-line)
Number of subjects: 132
Study 32487574 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires including EORTC-QLQ-C30, Decisional Conflict Scale, Control Preferences Scale, Quality-Quantity Questionnaire, treatment expectations, EORTC financial toxicity items, Work Ability Index, FACT-G items, Decisional Regret Scale
Number of subjects: 132
Study 32487642 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC/ctDNA combination assay
Number of subjects: 111
Study 32487642 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA assay
Number of subjects: 111
Study 32487642 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC assay
Number of subjects: 111
Study 32487642 — intervention group
Group type: COMPARATOR
Intervention: Conventional tumor marker
Number of subjects: 111
Study 32487675 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular strength training
Number of subjects: 118
Study 32487675 — intervention group
Group type: COMPARATOR
Intervention: No regular strength training (Control)
Number of subjects: 118
Study 32488055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored treatment strategy (TTS) guided by ex vivo drug sensitivity/resistance profiling (DSRP) and targeted next-generation sequencing (tNGS)
Number of subjects: 55
Study 32488055 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored treatment strategy (TTS)
Number of subjects: 55
Study 32488055 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 55
Study 32488236 — intervention group
Group type: EXPERIMENTAL
Intervention: 18F-FDG-PET/CT
Number of subjects: 140
Study 32488822 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D models of renal cell carcinoma (RCC) with venous tumor thrombus extension (VTE) for surgical simulation
Number of subjects: 0
Study 32488822 — intervention group
Group type: COMPARATOR
Intervention: Standard images (CT)
Number of subjects: 0
Study 32488989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib 40 mg single dose
Number of subjects: 44
Study 32488989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sapanisertib 30 mg once weekly
Number of subjects: 44
Study 32489644 — intervention group
Group type: EXPERIMENTAL
Intervention: One-day PAH-SYMPACT symptom reporting
Number of subjects: 0
Study 32489644 — intervention group
Group type: COMPARATOR
Intervention: Seven-day PAH-SYMPACT symptom reporting
Number of subjects: 0
Study 32489674 — intervention group
Group type: EXPERIMENTAL
Intervention: selfBACK app used for 6 weeks
Number of subjects: 51
Study 32489674 — intervention group
Group type: EXPERIMENTAL
Intervention: selfBACK app usage
Number of subjects: 51
Study 32489718 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm for measuring problem prescription opioid use
Number of subjects: 0
Study 32489805 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K antagonists (VKA)
Number of subjects: 1423
Study 32489805 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct oral anticoagulants (DOAC)
Number of subjects: 1423
Study 32489805 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic treatment
Number of subjects: 1423
Study 32489805 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet drugs (APD)
Number of subjects: 1423
Study 32489805 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall anticoagulation therapy patterns
Number of subjects: 1423
Study 32490026 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ACL and anterolateral ligament reconstruction (ACL + ALLR) with hamstring tendon autograft
Number of subjects: 224
Study 32490026 — intervention group
Group type: COMPARATOR
Intervention: Isolated ACL reconstruction (ACLR) with bone-patellar tendon-bone (BPTB) autograft
Number of subjects: 224
Study 32490026 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined ACL + ALLR
Number of subjects: 224
Study 32490026 — intervention group
Group type: COMPARATOR
Intervention: Isolated ACLR
Number of subjects: 224
Study 32490343 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 495
Study 32491152 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-related information avoidance (WIA) measured via a validated questionnaire
Number of subjects: 87
Study 32492067 — intervention group
Group type: EXPERIMENTAL
Intervention: LOCUS Bayesian method for multivariate proteomic QTL analysis
Number of subjects: 0
Study 32492069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg
Number of subjects: 1063
Study 32492069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg (injection frequency ≤4)
Number of subjects: 1063
Study 32492069 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5 mg (injection frequency ≥5)
Number of subjects: 1063
Study 32492125 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets or supplements containing 30%-155% of VA EARs for 42-90 d in Zambian children
Number of subjects: 213
Study 32492125 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets or supplements containing 30%-155% of VA EARs for 42-90 d in US women
Number of subjects: 213
Study 32492125 — intervention group
Group type: EXPERIMENTAL
Intervention: Diets or supplements containing 30%-155% of VA EARs for 42-90 d in Indonesian women
Number of subjects: 213
Study 32492942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol SR capsule (200-mg)
Number of subjects: 0
Study 32492942 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32492942 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 0
Study 32492942 — intervention group
Group type: COMPARATOR
Intervention: DAPT alone (clopidogrel and aspirin)
Number of subjects: 0
Study 32493044 — intervention group
Group type: EXPERIMENTAL
Intervention: GelrinC
Number of subjects: 56
Study 32493198 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow aspirate and biopsy
Number of subjects: 40
Study 32493206 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab 140-mg monthly by two subcutaneous 1-mL injections, given every 4 weeks for 12 weeks
Number of subjects: 100
Study 32493206 — intervention group
Group type: EXPERIMENTAL
Intervention: Erenumab
Number of subjects: 100
Study 32493217 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac MRI protocol added to breast MRI examination
Number of subjects: 0
Study 32493292 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcalorimetry of synovial fluid
Number of subjects: 107
Study 32493292 — intervention group
Group type: COMPARATOR
Intervention: Synovial fluid culture
Number of subjects: 107
Study 32493367 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher density of physicians (per 1000 people)
Number of subjects: 3588
Study 32493367 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater number of nurses (per 1000 people)
Number of subjects: 3588
Study 32493367 — intervention group
Group type: COMPARATOR
Intervention: Higher density of hospital beds (per 10,000 people)
Number of subjects: 3588
Study 32493448 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vitamin A supplementation (3000 UI/kg/die for 28 days)
Number of subjects: 62
Study 32493448 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin A supplementation)
Number of subjects: 62